Medscape7h
HFpEF and Obesity: Breakthrough Results With GLP-1 Therapies
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
Medscape1d
GLP-1 Therapies for HFpEF: Optimizing Outcomes Through Patient-Centered Care
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
Monthly Prescribing Reference14d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...
pulmonologyadvisor14d
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
The researchers found that 98 unique websites sold any GLP-1 RA during the study period; the analysis included 79 of these websites that sold compounded GLP-1 RAs or a prescription for compounded ...
Hosted on MSN14d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
GLP-1 RA initiation was not significantly associated with an increased overall risk for thyroid cancer versus the other diabetes drugs in the modified intention-to-treat analysis (hazard ratio [HR ...